Development of a First-in-Class Click Chemistry-Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial.

Clin Cancer Res · 2025 · PMC12402790 · PMID 40522144

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach significanceno p-value reported

S9C and S9D), failed to reach significance, suggesting that the CD8 + subpopulation predominantly drives T-cell–mediated responses to SQ3370.

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.